Posted on 13/01/2010 in Pharmaceutical Company Product News Novo Nordisk has started its UK-based investigations into the effectiveness of NN9924 - a long-acting oral GLP-1 (Glucagon-Like Peptide-1) analogue for which it has made a payment to Emisphere Technologies.
The firm paid a total of $2 million (1.23 million pounds) to the company, as its Eligen Technology was utilised for the establishment of the compound.
GLP-1, which is a natural hormone involved in controlling blood sugar levels, is being investigated for its safety, tolerability and bioavailability in individuals suffering from type 2 diabetes.
It stimulates the release of insulin when blood sugar levels become too high, as GLP-1 secretion is often impaired in those with the condition, the company highlighted.
Peter Kurtzhals, senior vice-president and head of diabetes research at Novo Nordisk, remarked: "We still have a long road with many challenges ahead of us before a GLP-1 pill becomes a reality."
Last week, Novo Nordisk announced its plans to work alongside Combine to conduct research into autoimmune disease therapies. Other news stories from 13/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
